This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi-Aventis, Eli Lilly, Novo Nordisk, Astrazeneca accused of conspiring over diabetes treatments

( July 30, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Mosaic Health filed a complaint accusing Sanofi-Aventis, Eli Lilly, Novo Nordisk, and Astrazeneca Pharmaceuticals conspired to retract a long-standing discount for safety-net hospitals and clinics. According to the complaint, the scheme allowed the companies to individually avoid competitive pressure and prevent individual market share losses, while restricting safety-net hospitals’ abilities to deliver robust and affordable healthcare options. As a result, the companies have been able to maintain their dominance over the markets for rapid analog insulins, long-acting analog insulins, and incretin mimetics.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections